英夫利西单抗治疗强直性脊柱炎的药物经济学系统评价

Systematic Evaluation of the Pharmacoeconomics of Infliximab in the Treatment of Ankylosing Spondylitis

目的:对英夫利西单抗治疗强直性脊柱炎的药物经济学文献进行系统评价。方法:分别从Web of Science、Ovid和Pub Med数据库中检索有关强直性脊柱炎及英夫利西单抗治疗的经济学评价的英文文献,采用系统回顾法对纳入的文献进行分析。结果:共纳入6篇文献进行系统分析,得出英夫利西单抗治疗强直性脊柱炎在英国、加拿大、荷兰和法国的增量成本效用比分别为35 400英镑、37 491加拿大元、67 207~237 010欧元和50 760~56 415欧元。结论:英夫利西单抗等生物制剂对强直性脊柱炎的治疗成本提出了很大的挑战,虽然有关英夫利西单抗治疗强直性脊柱炎的各个研究得出的增量成本效用比有所差异,但整体上仍保持在一个可接受的范围之内。

Objective：To understand of infliximab in the treatment of ankylosing spondylitis of pharmacoeconomic evaluation results, through the relevant literature. Methods：The English literature about economic evaluation of the treat- ment on ankylosing spondylitis with infliximab were researched from the databases via Web of Science, Ovid and PubMed. Then, using the systematic review method to analyze the relevant literature system. Results： A total of 6 articles were included for system analysis. Our study indicated that incremental cost effectiveness the ratios of the infliximab treatment of ankylosing spondylitis were ￡35 400, CND $ 37 491, 67 207 -23 701 and 50 760-6 56 415 in Britain, Canada, Holland and France respectively. Conclusion： Biological agent have showed the great challenges on the cost of treatment in patients with ankylosing spondylitis. Although the incremental cost effectiveness of each study of infliximab in the treatment of ankylosing spondylitis vary, the cost-effectiveness ratios for ankylosing spondylitis therapies remain within an acceptable range.